Suppr超能文献

治疗史和治疗剂量是肯尼亚西部单纯性疟疾儿童中磺胺多辛-乙胺嘧啶疗效的重要决定因素。

Treatment history and treatment dose are important determinants of sulfadoxine-pyrimethamine efficacy in children with uncomplicated malaria in Western Kenya.

作者信息

Terlouw Dianne J, Courval Jeanne M, Kolczak Margarette S, Rosenberg Oren S, Oloo Aggrey J, Kager Piet A, Lal Altaf A, Nahlen Bernard L, ter Kuile Feiko O

机构信息

Division of Parasitic Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia 30341, USA.

出版信息

J Infect Dis. 2003 Feb 1;187(3):467-76. doi: 10.1086/367705. Epub 2003 Jan 24.

Abstract

This study retrospectively studied amendable determinants of sulfadoxine-pyrimethamine (SP) efficacy involving 2869 treatments among 1072 Kenyan children <5 years old who had uncomplicated malaria. The dose was based on age: one-quarter tablet was given to infants <1 year old, one-half tablet was given to 1-3-year-old children, and a full tablet was given to 4-year-old children. Only 23.5% received the internationally recommended target dose of 25/1.25 mg of SP per kg of body weight. SP intake in the previous 15-35 days (adjusted relative risk, 1.67; 95% confidence interval, 1.35-2.07) and low SP dose (<27.5/1.375 mg/kg) (adjusted relative risk, 1.58; 95% confidence interval, 1.17-2.13) explained 38% of parasitological treatment failures by day 7. Patients with recent SP intake are likely to have recrudescent infections and may need close follow-up if treated with SP or alternative treatment. Applying our weight-for-age data to 31 existing age-based SP dose recommendations predicted that 22 of them would result in underdosing of >25% of children <5 years. Many age-based dose recommendations need urgent revision, because SP is increasingly used as first-line treatment in sub-Saharan Africa.

摘要

本研究回顾性分析了影响磺胺多辛-乙胺嘧啶(SP)疗效的可修正决定因素,研究对象为1072名患有非复杂性疟疾的肯尼亚5岁以下儿童,共涉及2869次治疗。剂量根据年龄确定:1岁以下婴儿服用四分之一片,1至3岁儿童服用半片,4岁儿童服用整片。只有23.5%的儿童接受了国际推荐的目标剂量,即每公斤体重25/1.25毫克的SP。在治疗前15至35天内服用过SP(调整后的相对风险为1.67;95%置信区间为1.35至2.07)以及低剂量SP(<27.5/1.375毫克/千克)(调整后的相对风险为1.58;95%置信区间为1.17至2.13)可解释7天内38%的寄生虫学治疗失败情况。近期服用过SP的患者可能会出现复发感染,如果使用SP或替代疗法进行治疗,可能需要密切随访。将我们的年龄别体重数据应用于31项现有的基于年龄的SP剂量推荐中,预计其中22项会导致5岁以下儿童中超过25%的儿童用药剂量不足。许多基于年龄的剂量推荐需要紧急修订,因为SP在撒哈拉以南非洲越来越多地被用作一线治疗药物。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验